Halozyme Adds Biotech Operations Veteran to Board Amid Growth Push
Event summary
- Halozyme appoints Dannielle Appelhans to its Board of Directors on August 18, 2026.
- Appelhans brings 20+ years of executive leadership in biotech and pharma, with expertise in operations, manufacturing, and supply chain management.
- She previously led COUR Pharmaceuticals, negotiating a $1 billion collaboration with Genentech, and served as CEO of Rubius Therapeutics.
- Appelhans' experience includes roles at Novartis, McKinsey & Company, and Eli Lilly and Company.
- Halozyme aims to leverage her expertise to scale ENHANZE, Hypercon, and Surf Bio technologies.
The big picture
Halozyme's appointment of Dannielle Appelhans underscores its focus on operational excellence as it scales its drug delivery technology platforms. Her background in executing large-scale partnerships and transforming global operations aligns with Halozyme's strategy to expand its royalty-driven business model. The move comes as the company seeks to leverage its ENHANZE, Hypercon, and Surf Bio technologies to create highly concentrated biologics and improve patient experiences.
What we're watching
- Strategic Partnerships
- How Appelhans' track record in executing major collaborations will impact Halozyme's growth strategy.
- Operational Scaling
- Whether her expertise in transforming global operations can accelerate the scaling of ENHANZE, Hypercon, and Surf Bio technologies.
- Market Expansion
- The pace at which Halozyme can expand its drug delivery technology portfolio and secure additional high-value partnerships.